In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.
Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Cox model after propensity score-matching, we found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The statin use-associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and randomized controlled trials involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic.
Zhang, X-J; Qin, J-J; Cheng, X; Shen, L; Zhao, Y-C; Yuan, Y; Lei, F; Chen, M-M; Yang, H; Bai, L; Song, X; Lin, L; Xia, M; Zhou, F; Zhou, J; She, Z-G; Zhu, L; Ma, X; Xu, Q; Ye, P; Chen, G; Liu, L; Mao, W; Yan, Y; Xiao, B; Lu, Z; Peng, G; Liu, M; Yang, J; Yang, L; Zhang, C; Lu, H; Xia, X; Wang, D; Liao, X; Wei, X; Zhang, B-H; Zhang, X; Yang, J; Zhao, G-N; Zhang, P; Liu, PP; Loomba, R; Ji, Y-X; Xia, J; Wang, Y; Cai, J; Guo, J; Li, H
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)